Proteomic biomarkers of peripheral blood mononuclear cells obtained from postmenopausal women undergoing an intervention with soy isoflavones

American Journal of Clinical Nutrition

Volumn 86, Issue 5, 2007, Pages 1369-1375

  Fuchs, Dagmar ^a   Vafeiadou, Katerina ^b   Hall, Wendy L ^b   Daniel, Hannelore ^a   Williams, Christine M ^b   Schroot, Joyce H ^c   Wenzel, Uwe ^d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF READING   (United Kingdom)

^c WAGENINGEN UNIVERSITY   (Netherlands)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Cardiovascular disease; Heat shock protein 70; Isoflavones; Peripheral blood mononuclear cells; Postmenopausal women; Proteome; Soy

Indexed keywords

ALPHA ENOLASE; BIOLOGICAL MARKER; GALECTIN 1; HEAT SHOCK PROTEIN 70; ISOFLAVONE; PHOSPHATASE; PLACEBO;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ADHESION; CELL PROLIFERATION; CEREAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DNA FINGERPRINTING; FEMALE; FIBRINOLYSIS; GEL ELECTROPHORESIS; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTMENOPAUSE; PROTEOMICS; SOYBEAN;

EID: 36248931106     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/86.5.1369     Document Type: Article

References (47)

1. Yutani C, Imakita M, Ishibashi-Ueda H, Tsukamoto Y, Nishida N, Ikeda Y. Coronary atherosclerosis and interventions: pathological sequences and restenosis. Pathol Int 1999;49:273-90.
2. Barrett-Connor E. Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation 1997;95:252-64.
3. Erberich LC, Alcantara VM, Picheth G, Scartezini M. Hormone replacement therapy in postmenopausal women and its effects on plasma lipid levels. Clin Chem Lab Med 2002;40:446-51.
4. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288:872-81.
5. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999;100:717-22.
6. Tormey SM, Malone CM, McDermott EW, O'Higgins NJ, Hill AD. Current status of combined hormone replacement therapy in clinical practice. Clin Breast Cancer 2006;6(suppl):S51-7.
7. Scheiber MD, Liu JH, Subbiah MT, Rebar RW, Setchell KD. Dietary inclusion of whole soy foods results in significant reductions in clinical risk factors for osteoporosis and cardiovascular disease in normal postmenopausal women. Menopause 2001;8:384-92.
8. Steinberg FM, Guthrie NL, Villablanca AC, Kumar K, Murray MJ. Soy protein with isoflavones has favorable effects on endothelial function that are independent of lipid and antioxidant effects in healthy postmenopausal women. Am J Clin Nutr 2003;78:123-30.
9. Sirtori CR, Lovati MR. Soy proteins and cardiovascular disease. Curr Atheroscler Rep 2001;3:47-53.
10. Crouse JR III, Morgan T, Terry JG, Ellis J, Vitolins M, Burke GL. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med 1999;159:2070-6.
11. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006;113:1034-44.
12. Reimann M, Dierkes J, Carlsohn A, et al. Consumption of soy isoflavones does not affect plasma total homocysteine or asymmetric dimethylarginine concentrations in healthy postmenopausal women. J Nutr 2006;136:100-5.
13. Hall WL, Vafeiadou K, Hallund J, et al. Soy-isoflavone-enriched foods and inflammatory biomarkers of cardiovascular disease risk in postmenopausal women: interactions with genotype and equol production. Am J Clin Nutr 2005;82:1260-8;
14. Hall WL, Vafeiadou K, Hallund J, et al. Soy-isoflavone-enriched foods and markers of lipid and glucose metabolism in postmenopausal women: interactions with genotype and equol production. Am J Clin Nutr 2006;83:592-600.
15. Hallund J, Bugel S, Tholstrup T, et al. Soya isoflavone-enriched cereal bars affect markers of endothelial function in postmenopausal women. Br J Nutr 2006;95:1120-6.
16. Görg A, Obermaier C, Boguth G, et al. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 2000;21:1037-53.
17. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
18. Walters J, Skene D, Hampton SM, Ferns GA Biological rhythms, endothelial health and cardiovascular disease. Med Sci Monit 2003;9:RA1-8.
19. Pfeilschifter J, Koditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002;23:90-119.
20. Cassidy A, Hooper L. Phytoestrogens and cardiovascular disease. J Br Menopause Soc 2006;12:49-56.
21. US Department of Health and Human Services, Food and Drug Administration. Food labeling: health claims; soy protein and coronary heart disease. Final rule. Fed Regist 1999;64:57699-733.
22. Tonstad S, Smerud K, Hoie L. A comparison of the effects of 2 doses of soy protein or casein on serum lipids, serum lipoproteins, and plasma total homocysteine in hypercholesterolemic subjects. Am J Clin Nutr 2002;76:78-84.
23. Anthony MS. Soy and cardiovascular disease: cholesterol lowering and beyond. J Nutr 2000;130(suppl):662S-3S.
24. Tikkanen MJ, Wahala K, Ojala S, Vihma V, Adlercreutz H. Effect of soybean phytoestrogen intake on low density lipoprotein oxidation resistance. Proc Natl Acad Sci U S A 1998;95:3106-10.
25. Vafeiadou K, Hall WL, Williams CM. Does genotype and equol-production status affect response to isoflavones? Data from a pan-European study on the effects of isoflavones on cardiovascular risk markers in post-menopausal women. Proc Nutr Soc 2006;65:106-15.
26. Debey S, Zander T, Brors B, Popov A, Eils R, Schultze JL. A highly standardized, robust, and cost-effective method for genome-wide transcriptome analysis of peripheral blood applicable to large-scale clinical trials. Genomics 2006;87:653-64.
27. Forrest MS, Lan Q, Hubbard AE, et al. Discovery of novel biomarkers by microarray analysis of peripheral blood mononuclear cell gene expression in benzene-exposed workers. Environ Health Perspect 2005;113:801-7.
28. Ludewig B, Laman JD The in and out of monocytes in atherosclerotic plaques: balancing inflammation through migration. Proc Natl Acad Sci U S A 2004;101:11529-30.
29. Osiecki H. The role of chronic inflammation in cardiovascular disease and its regulation by nutrients. Altern Med Rev 2004;9:32-53.
30. Meng X, Harken AH. The interaction between Hsp70 and TNF-alpha expression: a novel mechanism for protection of the myocardium against post-injury depression. Shock 2002;17:345-53.
31. Shioi A, Katagi M, Okuno Y, et al. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. Circ Res 2002;91:9-16.
32. Kevil CG, Pruitt H, Kavanagh TJ, et al. Regulation of endothelial glutathione by ICAM-1: implications for inflammation. FASEB J 2004;18:1321-3.
33. Delogu G, Signore M, Mechelli A, Famularo G. Heat shock proteins and their role in heart injury. Curr Opin Crit Care 2002;8:411-6.
34. Pockley AG, Georgiades A, Thulin T, de Faire U, Frostegard J. Serum heat shock protein 70 levels predict the development of atherosclerosis in subjects with established hypertension. Hypertension 2003;42:235-8.
35. Zhu J, Quyyumi AA, Wu H, et al. Increased serum levels of heat shock protein 70 are associated with low risk of coronary artery disease. Arterioscler Thromb Vasc Biol 2003;23:1055-9.
36. Jamsa E, Simonen M, Makarow M. Selective retention of secretory proteins in the yeast endoplasmic reticulum by treatment of cells with a reducing agent. Yeast 1994;10:355-70.
37. Leonardi A, Ellinger-Ziegelbauer H, Franzoso G, Brown K, Siebenlist U. Physical and functional interaction of filamin (actin-binding protein-280) and tumor necrosis factor receptor-associated factor 2. J Biol Chem 2000;275:271-8.
38. Grisham MB, Palombella VJ, Elliott PJ, et al. Inhibition of NF-kappa B activation in vitro and in vivo: role of 26S proteasome Methods Enzymol 1999;300:345-63.
39. Mustelin T, Vang T, Bottini N. Protein tyrosine phosphatases and the immune response. Nat Rev Immunol 2005;5:43-57.
40. Peng X, Mehta R, Wang S, Chellappan S, Mehta RG. Prohibitin is a novel target gene of vitamin D involved in its antiproliferative action in breast cancer cells. Cancer Res 2006;66:7361-9.
41. Lutomski D, Fouillit M, Bourin P, et al. Externalization and binding of galectin-1 on cell surface of K562 cells upon erythroid differentiation. Glycobiology 1997;7:1193-9.
42. Moiseeva EP, Williams B, Goodall AH, Samani NJ. Galectin-1 interacts with beta-1 subunit of integrin. Biochem Biophys Res Commun 2003;310:1010-6.
43. Kannel WB. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 2005;40:1215-20.
44. Lopez-Alemany R, Longstaff C, Hawley S, et al. Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase. Am J Hematol 2003;72:234-42.
45. Yang ES, Yang JH, Park JE, Park JW. Oxalomalate, a competitive inhibitor of NADP+-dependent isocitrate dehydrogenase, regulates lipid peroxidation-mediated apoptosis in U937 cells. Free Radic Res 2005;39:89-94.
46. Maeng O, Kim YC, Shin HJ, et al. Cytosolic NADP(+)-dependent isocitrate dehydrogenase protects macrophages from LPS-induced nitric oxide and reactive oxygen species. Biochem Biophys Res Commun 2004;317:558-64.
47. Hossain GS, van Thienen JV, Werstuck GH, et al. TDAG51 is induced by homocysteine, promotes detachment-mediated programmed cell death, and contributes to the development of atherosclerosis in hyperhomocysteinemia. J Biol Chem 2003;278:30317-27.